BRCA2 and ovarian serous adenocarcinoma: Finally, we report potentially cis-acting regulatory variants in the BRCA2 gene that are associated with varied expression of BRCA2. In summary, our study contributes to a better understanding of the biological mechanisms underlying chemotherapy response in high-grade serous ovarian cancer.